Literature DB >> 31184934

Quantitative contrast-enhanced perfusion kinetics in multiparametric MRI in differentiating prostate cancer from chronic prostatitis: results from a pilot study.

Binit Sureka1, Poonam Elhence2, Pushpinder Singh Khera1, Gautam Ram Choudhary3, Himanshu Pandey3, Pawan Kumar Garg1, Kuldeep Yadav1, Akhil Goel4.   

Abstract

OBJECTIVE: The objectives of the study were to analyze the apparent diffusion coefficient (ADC), ktrans, kep metrics in dynamic contrast-enhanced multiparametric MRI (DCE-mpMRI) in biopsy proven cases of prostate cancer (PCa) and prostatitis and to establish "cut-off" values for various pharmacokinetic parameters that may distinguish PCa from chronic prostatitis.
METHODS: A retrospective review of all cases of PCa and chronic prostatitis patients, who underwent DCE-mpMRI in our institute was done from July 2017 to January 2019. Mean ADC, ktrans , kep for lesion "L" (ADCL, ktrans L , kepL) and normal prostate tissue "N" (ADCN, ktrans N , kepN ,) were calculated for each region of interest. Different ratios ADC ratio (defined as ADCL/ ADCN), ktrans ratio (ktrans L/ ktrans N), kepratio (kepL/kepN) were calculated to differentiate PCa from chronic prostatitis.
RESULTS: Total of biopsy proven 14 cases of PCa and 18 cases of chronic prostatitis were included in the study. For ktrans ratio, the optimal cut-off was at 1.49 units where sensitivity was 85.7%, specificity was 61.1 % and Youden's index was 0.468 %. Similarly, optimal cut-offs determined for kep lesion was 0.86 (sensitivity 85.7%, specificity 66.7%, J = 0.524) and for kep ratio was 1.34 units (sensitivity 78.6%, specificity 66.7%, J = 0.543).
CONCLUSION: DCE-mpMRI metrics could differentiate between PCa and chronic prostatitis with good specificity and sensitivity, while ProstateImaging Reporting and Data System v. 2 alone, did not differentiate between these patterns. ADVANCES IN KNOWLEDGE: ktrans ratio, kep lesion and kep ratio can differentiate PCa from chronic prostatitis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31184934      PMCID: PMC6724635          DOI: 10.1259/bjr.20190181

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  13 in total

1.  Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology.

Authors:  Piotr Kozlowski; Silvia D Chang; Edward C Jones; Kenneth W Berean; Henry Chen; S Larry Goldenberg
Journal:  J Magn Reson Imaging       Date:  2006-07       Impact factor: 4.813

2.  Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging.

Authors:  Chan Kyo Kim; Byung Kwan Park; Bohyun Kim
Journal:  J Comput Assist Tomogr       Date:  2006 Jan-Feb       Impact factor: 1.826

Review 3.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

Review 4.  Advancements in MR imaging of the prostate: from diagnosis to interventions.

Authors:  David Bonekamp; Michael A Jacobs; Riham El-Khouli; Dan Stoianovici; Katarzyna J Macura
Journal:  Radiographics       Date:  2011 May-Jun       Impact factor: 5.333

5.  MpMRI of the prostate: is there a role for semi-quantitative analysis of DCE-MRI and late gadolinium enhancement in the characterisation of prostate cancer?

Authors:  G Cristel; A Esposito; A Briganti; A Damascelli; G Brembilla; M Freschi; A Ambrosi; F Montorsi; A Del Maschio; F De Cobelli
Journal:  Clin Radiol       Date:  2019-02-08       Impact factor: 2.350

Review 6.  Prostatic fibrosis, lower urinary tract symptoms, and BPH.

Authors:  Jose A Rodriguez-Nieves; Jill A Macoska
Journal:  Nat Rev Urol       Date:  2013-07-16       Impact factor: 14.432

7.  Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters.

Authors:  Iclal Ocak; Marcelino Bernardo; Greg Metzger; Tristan Barrett; Peter Pinto; Paul S Albert; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2007-10       Impact factor: 3.959

8.  Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?

Authors:  Heinz-Peter Schlemmer; Jonas Merkle; Rainer Grobholz; Tim Jaeger; Maurice Stephan Michel; Axel Werner; Jan Rabe; Gerhard van Kaick
Journal:  Eur Radiol       Date:  2003-10-03       Impact factor: 5.315

9.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

10.  Quantitative parameters in dynamic contrast-enhanced magnetic resonance imaging for the detection and characterization of prostate cancer.

Authors:  Cheng Wei; Bowen Jin; Magdalena Szewczyk-Bieda; Stephen Gandy; Stephen Lang; Yilong Zhang; Zhihong Huang; Ghulam Nabi
Journal:  Oncotarget       Date:  2018-03-23
View more
  4 in total

1.  Dynamic contrast-enhanced magnetic resonance imaging for risk stratification in patients with prostate cancer.

Authors:  Hyungin Park; Seung Ho Kim; Joo Yeon Kim
Journal:  Quant Imaging Med Surg       Date:  2022-01

2.  Dynamic Contrast Enhanced Study in Multiparametric Examination of the Prostate-Can We Make Better Use of It?

Authors:  Silva Guljaš; Mirta Benšić; Zdravka Krivdić Dupan; Oliver Pavlović; Vinko Krajina; Deni Pavoković; Petra Šmit Takač; Matija Hranić; Tamer Salha
Journal:  Tomography       Date:  2022-06-09

3.  Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions.

Authors:  Katja Bogner; Karl Engelhard; Wolfgang Wuest; Sajad Hamel
Journal:  Abdom Radiol (NY)       Date:  2022-03-21

4.  Impact of Chronic Prostatitis on the PI-RADS Score 3: Proposal for the Addition of a Novel Binary Suffix.

Authors:  Sascha Merat; Theresa Blümlein; Markus Klarhöfer; Dominik Nickel; Gad Singer; Frank G Zöllner; Stefan O Schoenberg; Rahel A Kubik-Huch; Daniel Hausmann; Lukas Hefermehl
Journal:  Diagnostics (Basel)       Date:  2021-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.